XL-protein GmbH

General information

XL-protein GmbH
Lise-Meitner-Str. 30
85354 Freising, Bavaria
Germany

Contact person: Claus Schalper, Chief Business Officer & Founder
Company main phone: +49 (8161) 5373090
Company main fax: +49 (8161) 5373099
Website: https://www.xl-protein.com

Year founded:	2009
Source of foundation:	Spin-off from university
Name of foundation source:	Insitute of Biological Chemistry at the Technische Universität München (TUM)

Corporate description / mission:
XL-protein GmbH is a privatly owned German biotech company commercializing the revolutionary 'PASylation' technology, which allows the extension of the plasma half-life of biopharmaceuticals. The company will focus on the preclinical as well clinical development of PASylated proteins in several disease areas.

State of ownership: Private / independent
Headquarters: HQ: Yes

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Proteins

Primary therapeutic areas:

Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the eye / ophthalmology
Diseases of the nervous system / neurology
Endocrine, nutritional and metabolic diseases / endocrinology
Infectious and parasitic diseases / infectiology / parasitology
Injury, poisoning and certain other consequences of external causes / toxicology
Musculoskeletal system and connective tissue / Orthopedics
Neoplasms / cancer / oncology

Business model:

In-licensing
Out-licensing
R&D

Customer segments:

Hospitals
Large biotech & big pharma
Small biotech

Summary Products / Services / Technologies

Technology used:
PASYLATION® Technology